Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 215.6 SEK 3.65% Market Closed
Market Cap: 29.2B SEK
Have any thoughts about
Vitrolife AB?
Write Note

P/E
Price to Earnings

-7.7
Current
63.3
Median
22.1
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-7.7
=
Market Cap
29.2B SEK
/
Net Income
-3.8B SEK
All Countries
Close
Market Cap P/E
SE
Vitrolife AB
STO:VITR
29.2B SEK -7.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 740.1
US
Abbvie Inc
NYSE:ABBV
309B USD 60.8
US
Amgen Inc
NASDAQ:AMGN
141B USD 33.3
US
Gilead Sciences Inc
NASDAQ:GILD
116B USD 920.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.5B USD -215.8
US
Epizyme Inc
F:EPE
94.1B EUR -472.7
AU
CSL Ltd
ASX:CSL
134.4B AUD 31.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 16.8
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
36B EUR -135.6
Earnings Growth P/E to Growth
SE
Vitrolife AB
STO:VITR
Average P/E: 212.6
Negative Multiple: -7.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
60.8
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.3
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
920.3
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -215.8
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
53.6
2-Years Forward
P/E
43.9
3-Years Forward
P/E
37.3

See Also

Discover More